Shauna Campbell, MD of Cleveland Clinic answers a question received from colleagues: how does it differ from previously published nomograms?
_______
The integration of prostate-specific antigen (PSA) kinetics into a nomogram widely used to predict outcomes of salvage therapy offers physicians and patients a more nuanced, longer-term look at prostate cancer-specific outcomes.
In 2007, a multi-institutional cohort led by Cleveland Clinicรขโฌโขs Glickman Urological and Kidney Instituteรย developedรย a nomogram to predict prostate cancer-specific and all-cause mortality at six years after salvage radiotherapy (SRT).
Almost a decade later, aรย studyรย led by Cleveland Clinic Cancer Center radiation oncologistรย Rahul D. Tendulkar, MD, updated the nomogram with evidence that early initiation of SRT following radical prostatectomy (RP) reduced biochemical failure (BF) and distant metastases (DM).
The researchersรขโฌโข most recent update to the nomogram was presented at the 2019 annual meeting of the American Society for Radiation Oncology (ASTRO).
รขโฌลOne critique of our previous update was the lack of PSA kinetics among the predictive factors,รขโฌย says Shauna Campbell, DO, chief resident, radiation oncology, Cleveland Clinic. รขโฌลThis version of the nomogram adds initial postoperative PSA level and PSA doubling time [PSADT] to the picture.รขโฌย
Read the rest here:รย https://consultqd.clevelandclinic.org/postprostatectomy-prostate-specific-antigen-kinetics-associated-with-recurrence-after-salvage-radiation/